

## PFIZER VENTURES TEAM

### BARBARA DALTON, PHD

*Vice President, WWBD and  
Senior Managing Partner at Pfizer Ventures*

**Barbara.Dalton@pfizer.com**

### DENIS PATRICK, PHD

*Vice President WRDM and Managing Partner at Pfizer Ventures*

**Denis.Patrick@pfizer.com**

### NIKOLA TRBOVIC, PHD

*Executive Director, WRDM and Partner at Pfizer Ventures*

**Nikola.Trbovic@pfizer.com**

### CHRISTOPHER O'DONNELL, PHD

*Executive Director, WRDM and Partner at Pfizer Ventures*

**Christopher.J.ODonnell@pfizer.com**

### RANA AL-HALLAQ, PHD

*Senior Director, WWBD and Partner at Pfizer Ventures*

**Rana.Al-Hallaq@pfizer.com**

### MICHAEL BARAN, MBA, PHD

*Executive Director, WRDM and Partner at Pfizer Ventures*

**Michael.Baran@pfizer.com**

## HOW WE WORK

- Active investor, working with management to develop product strategy and build shareholder value.
- Bring Pfizer pedigree and perspective to our portfolio companies, providing the ability to utilize the network, expertise and resources of Pfizer for their benefit.
- Potential for Pfizer business development relationship whenever appropriate.

With a \$600M capital investment from Pfizer for private investments, Pfizer Ventures invests in private companies at all stages of development, with a strong focus on early stage opportunities. Other investments, including startups, spinouts and consortia opportunities, will also be considered. We actively work with our current portfolio companies throughout their growth cycles, contributing strategic guidance in addition to our capital and providing access to internal Pfizer expertise, whenever appropriate. While primarily U.S. focused, international investments may represent up to 20% of the portfolio. We have the ability to lead or join a syndicate of investors and will seek board representation commensurate with our investment.



Pfizer Ventures, the venture capital arm of Pfizer Inc., was founded in 2004 and invests for return in areas of current or future strategic interest to Pfizer. Pfizer Ventures seeks to remain at the forefront of life science advances, looking to identify and invest in emerging companies that are developing transformative medicines and technologies that have the potential to enhance Pfizer's pipeline and shape the future of our industry.



*For additional information,  
please visit our website  
[www.pfizerventures.com](http://www.pfizerventures.com)*

## INVESTMENT STRATEGY

- Primarily focused on potentially transformative therapeutics, with an emphasis on Pfizer's core therapeutic areas; Oncology, Rare Disease, Inflammation and Immunology, Internal Medicine and Vaccines.
- Focus also includes neuroscience investments, following Pfizer's decision to continue advancing research in this critical area of unmet medical need through a venture capital strategy.
- Will also consider platform technologies, diagnostics, drug delivery, pharmaceutical services and other technologies that have the potential to transform drug discovery and development.

<b>Geography</b>	<ul style="list-style-type: none"> <li>• U.S. focused</li> <li>• Approximately 20% of investments may be outside U.S.</li> </ul>
<b>Investment Type</b>	<ul style="list-style-type: none"> <li>• Direct investing</li> <li>• All stages possible, with focus on early stage</li> </ul>
<b>Returns</b>	<ul style="list-style-type: none"> <li>• Strategic and financial</li> <li>• Measured over long term</li> </ul>
<b>Funding</b>	<ul style="list-style-type: none"> <li>• \$600M capital commitment from Pfizer</li> <li>• Up to \$10M in first investment; reserved allocation for follow-on investments</li> </ul>
<b>Syndication</b>	<ul style="list-style-type: none"> <li>• Invest as member of a syndicate, lead where appropriate</li> <li>• Syndicate member located near company critical</li> </ul>
<b>Collaboration</b>	<ul style="list-style-type: none"> <li>• Potential for business relationship with Pfizer considered in investment criteria</li> <li>• Can be transacted in parallel with investment or explored in the future</li> </ul>
<b>Influence in Development</b>	<ul style="list-style-type: none"> <li>• Contribute capital and industry experience to help guide development and company growth</li> <li>• Scientific advisory board participation desired</li> </ul>
<b>Control</b>	<ul style="list-style-type: none"> <li>• Minority ownership positions</li> <li>• Board seats where appropriate</li> </ul>
<b>Deal Structure</b>	<ul style="list-style-type: none"> <li>• Traditional VC investment</li> <li>• Product rights not required</li> </ul>

## ACTIVE PORTFOLIO COMPANIES

### 4D Molecular Therapeutics

Emeryville, CA  
4dmolecularterapeutics.com

### Accelerator Corporation

New York, NY  
acceleratorcorp.com

### Adapsyn Bioscience

Hamilton, Ontario, CA  
adapsyn.com

### AMRA

Linköping, Sweden  
amra.se

### AnToIRx

Cambridge, MA  
antolrx.com

### Aquinnah Pharmaceuticals

Cambridge, MA  
aquinnahpharma.com

### Arkuda Therapeutics

Cambridge, MA  
arkudatx.com

### Arrakis Therapeutics

Waltham, MA  
arrakistx.com

### Artios Pharma

Cambridge, UK  
artiospharma.com

### Autifony Therapeutics

London, UK  
autifony.com

### Autobahn Therapeutics

San Diego, CA  
autobahntx.com

### BioAtla

San Diego, CA  
bioatla.com

### BioGraph 55

San Francisco, CA

### BioNTech

Mainz, Germany  
biontech.de

### Blade Therapeutics

South San Francisco, CA  
blademed.com

### BlueLight Therapeutics

South San Francisco, CA  
bluelighttx.com

### Bolt Biotherapeutics

Redwood City, CA  
boltbio.com

### Cortexyme

South San Francisco, CA  
cortexyme.com

### Cydan II, Inc.

Boston, MA  
cydanco.com

### eFFECTOR Therapeutics

San Diego, CA  
effector.com

### Epic Sciences

La Jolla, CA  
epicsciences.com

### EvolveImmune Therapeutics

Westport, CT  
evolveimmune.com

### FoRx Therapeutics

Basel, Switzerland  
forxtherapeutics.com

### G-CON Manufacturing

Bryan, TX  
gconbio.com

### Imara

Cambridge, MA  
imaratx.com

### ImCheck Therapeutics

Marseille, France  
imchecktherapeutics.com

### ImmunOs Therapeutics

Schlieren, Switzerland  
immunostherapeutics.com

### Ixchelsis Limited

Sandwich, UK  
ixchelsis.com

### Jnana Therapeutics

Boston, MA  
jnanatx.com

### Kymera Therapeutics

Cambridge, MA  
kymeratx.com

### Levcept Limited

Sandwich, UK  
levcept.com

### Lodo Therapeutics

New York, NY  
lodotherapeutics.com

### Magnolia Neurosciences

New York, NY  
magnolianeurosciences.com

### Mediar Therapeutics

Cambridge, MA  
mediartx.com

### Mersana Therapeutics

Cambridge, MA  
mersana.com

### Metabomed

Yavne, Israel  
metabomed.com

### MISSION Therapeutics

Cambridge, UK  
missiontherapeutics.com

### Montis Biosciences

Leuven, Belgium  
montisbiosciences.com

### Morphic Therapeutic

Waltham, MA  
morphictx.com

### National Resilience

La Jolla, CA  
resilience.com

### Neuronetics

Malvern, PA  
neuronetics.com

### NextCure

Beltsville, MD  
nextcure.com

### Nimbus Therapeutics

Cambridge, MA  
nimbustx.com

### Palleon Pharma

Waltham, MA  
palleonpharma.com

### Pyxis Oncology

Cambridge, MA  
pyxisoncology.com

### RefleXion Medical

Hayward, CA  
reflexionmedical.com

### Rhythm Pharmaceuticals

Boston, MA  
rhythmtx.com

### Second Genome

South San Francisco, CA  
secondgenome.com

### SpringWorks Therapeutics

Stamford, CT  
springworkstx.com

### Storm Therapeutics

Cambridge, UK  
stormtherapeutics.com

### Strata Oncology

Ann Arbor, MI  
strataoncology.com

### System1 Biosciences

San Francisco, CA  
system1.bio

### Translate Bio

Cambridge, MA  
translate.bio

### TRex Bio

South San Francisco, CA  
trex.bio

### Triplet Therapeutics

Cambridge, MA  
tripletttx.com

### VectivBio

Basel, Switzerland  
vectivbio.com

### Yumanity Therapeutics

Cambridge, MA  
yumanity.com